Testosterone Replacement Therapy, Honestly Assessed
Evidence, risks, and who it's actually for
Testosterone replacement therapy (TRT) has become significantly more prominent in popular health discussion in recent years — and the evidence base has genuinely evolved alongside that attention, including one major recent trial that meaningfully changed the risk picture.
Who It's Actually For
The Endocrine Society's clinical practice guideline recommends diagnosing hypogonadism based on the combination of genuine symptoms and consistently, unambiguously low testosterone confirmed on repeat blood testing — not on a single reading, and not on symptoms alone[10]. This is a meaningfully more conservative bar than the popular framing around "optimising" testosterone that's become common, and the guideline explicitly notes that many men are prescribed testosterone without this appropriate diagnostic workup.
The Cardiovascular Safety Question, Recently Answered
For years, cardiovascular risk was a significant, somewhat unresolved concern around TRT. A large randomised trial of over 5,200 men aged 45–80 with confirmed hypogonadism and either existing or high risk of cardiovascular disease found that testosterone therapy didn't raise the risk of a heart attack, stroke, or cardiovascular death compared with placebo — a reassuring result for the population most likely to have been worried about this risk (in trial terms, it was non-inferior to placebo on this composite endpoint)[11]. The same trial did find higher rates of some other specific issues in the testosterone group — pulmonary embolism, abnormal heart rhythms including atrial fibrillation, and acute kidney injury. Bottom line: safe for the primary outcome, with a few specific elevated risks worth discussing individually with a prescriber.
The Genuine Risks of Misuse
Using TRT to push already-normal testosterone levels higher — rather than treating confirmed clinical deficiency — carries real, well-documented risks: suppression of natural testosterone production (since the body senses adequate levels and stops signalling for more), which can cause infertility and testicular shrinkage; increased red blood cell production, raising clotting risk; and the cardiovascular nuances covered above, which were studied specifically in a genuinely hypogonadal population, not in men with normal testosterone electively raising it further.
Section takeaway
TRT is appropriate, well-studied, and — per the largest recent safety trial — not associated with excess overall cardiovascular events in men with confirmed hypogonadism and cardiovascular risk, though a few specific risks (blood clots, arrhythmia) were elevated and worth discussing individually. It remains a treatment for confirmed clinical deficiency, not a general optimisation tool for men with already-normal levels — that use case carries real, separate risks the safety trial wasn't designed to address.